Emergence_NN of_IN Klebsiella_NP pneumoniae_NP Isolates_NP Producing_NP Inducible_NP DHA-1_NP beta-Lactamase_NN in_IN a_DT University_NP Hospital_NP in_IN Taiwan_NP Ten_CD nonrepetitive_JJ clinical_JJ isolates_NNS of_IN Klebsiella_NP pneumoniae_NNS exhibiting_VBG an_DT unusual_JJ inducible_JJ beta-lactam_NN resistance_NN phenotype_NN were_VBD identified_VBN between_IN January_NP 1999_CD and_CC September_NP 2001_CD in_IN a_DT university_NN hospital_NN in_IN Taiwan_NP ._SENT In_IN the_DT presence_NN of_IN 2_CD mug_NN of_IN clavulanic_JJ acid_NN ,_, the_DT isolates_NNS showed_VBD a_DT one_CD to_TO four_CD twofold_JJ concentration_NN increase_NN in_IN the_DT MICs_NN of_IN ceftazidime_NN ,_, cefotaxime_NN ,_, and_CC aztreonam_NP but_CC remained_VBD susceptible_JJ to_TO cefepime_NP (_( MICs_NP ,_, <=0.5_NN mug/ml_NN )_) and_CC imipenem_NP (_( MICs_NP ,_, <=0.5_NN mug/ml_NN )_) ._SENT PCR_NP ,_, sequence_NN analysis_NN ,_, and_CC isoelectric_JJ focusing_VBG revealed_VBN production_NN by_IN these_DT isolates_NNS of_IN TEM-1_NP ,_, SHV-11_NP ,_, and_CC DHA-1_NP ,_, a_DT plasmid-encoded_JJ inducible_JJ AmpC_NP beta-lactamase_NN originally_RB found_VBD in_IN a_DT Salmonella_NP enterica_NP serovar_NP Enteritidis_NP strain_NN ._SENT Transfer_NN of_IN the_DT resistance_NN by_IN conjugation_NN experiments_NNS was_VBD not_RB successful_JJ ,_, but_CC Southern_NP hybridization_NN showed_VBD that_IN blaDHA-1_NN was_VBD located_VBN on_IN 70-kb_JJ plasmids_NNS ,_, suggesting_VBG that_IN the_DT blaDHA-1-containing_VBG plasmids_NNS in_IN the_DT K._NP pneumoniae_NN isolates_NNS were_VBD non-self-transmissible_JJ ._SENT Five_CD isolates_NNS were_VBD recovered_VBN from_IN patients_NNS in_IN two_CD surgery_NN wards_NNS and_CC two_CD intensive_JJ care_NN units_NNS ._SENT Acquisition_NN of_IN the_DT DHA-1_NP producers_NNS could_MD be_VB traced_VBN back_RB to_TO previous_JJ hospitalizations_NNS 1_CD to_TO 5_CD months_NNS earlier_RBR for_IN the_DT other_JJ five_CD patients_NNS ._SENT Six_CD and_CC seven_CD patterns_NNS among_IN the_DT isolates_NNS were_VBD demonstrated_VBN by_IN plasmid_NP analysis_NN and_CC ribotyping_NN ,_, respectively_RB ,_, indicating_VBG that_IN the_DT spread_NN of_IN the_DT DHA-1_NP producers_NNS was_VBD due_JJ to_TO both_DT horizontal_JJ transfer_NN of_IN blaDHA-1_NN and_CC dissemination_NN of_IN endemic_JJ clones_NNS ._SENT Chromosome-mediated_NP AmpC_NP beta-lactamases_NNS have_VBP been_VBN described_VBN in_IN a_DT wide_JJ variety_NN of_IN gram-negative_JJ bacilli_NNS ,_, such_JJ as_IN Pseudomonas_NP aeruginosa_NP and_CC Enterobacter_NP spp._NP ._SENT In_IN most_JJS genera_NNS of_IN the_DT family_NN Enterobacteriaceae_NP ,_, AmpC_NP is_VBZ inducible_JJ and_CC ,_, when_WRB overexpressed_VBN ,_, can_MD confer_VB resistance_NN to_TO both_DT oxyimino-_NN and_CC 7-alpha-methoxy-cephalosporins_NNS and_CC monobactams_NNS ._SENT Many_JJ plasmid-mediated_JJ AmpC_NP enzymes_NNS ,_, such_JJ as_IN CMY-type_NP beta-lactamases_NNS ,_, have_VBP been_VBN found_VBN in_IN bacterial_JJ species_NNS that_WDT naturally_RB lack_VBP a_DT chromosomal_JJ AmpC_NP beta-lactamase_NN ,_, such_JJ as_IN Klebsiella_NP pneumoniae_NNS ,_, Proteus_NP mirabilis_NP ,_, and_CC Salmonella_NP spp._NP (_( ,_, -_: ,_, -_: ,_, ,_, ,_, )_) ._SENT It_PP is_VBZ believed_VBN that_IN such_JJ beta-lactamases_NNS arose_VBD through_IN the_DT transfer_NN of_IN chromosomal_JJ AmpC_NP genes_NNS onto_IN plasmids_NNS ._SENT Unlike_IN chromosome-mediated_JJ AmpC_NP ,_, plasmid-encoded_JJ AmpC_NP enzymes_NNS are_VBP almost_RB always_RB expressed_VBN constitutively_RB (_( -_: ,_, -_: ,_, ,_, )_) ._SENT Plasmid-mediated_JJ inducible_JJ beta-lactamases_NNS are_VBP extremely_RB rare_JJ ._SENT DHA-1_NN from_IN a_DT clinical_JJ isolate_NN of_IN Salmonella_NP enterica_NP serovar_NP Enteritidis_NP from_IN Saudi_NP Arabia_NP is_VBZ the_DT first_RB identified_VBN plasmid-encoded_JJ inducible_JJ cephalosporinase_NN ._SENT The_DT counterpart_NN of_IN blaDHA-1_NN was_VBD the_DT chromosomal_JJ AmpC_NP gene_NN of_IN Morganella_NP morganii_NP ._SENT The_DT inducibility_NN of_IN DHA-1_NP is_VBZ due_JJ to_TO the_DT presence_NN of_IN a_DT regulator_NN ampR_NN gene_NN ,_, which_WDT is_VBZ also_RB related_VBN to_TO that_DT of_IN M._NP morganii_NP ,_, upstream_RB of_IN blaDHA-1_NN on_IN the_DT same_JJ plasmid_NN ._SENT A_DT DHA-1-related_JJ beta-lactamase_NN ,_, named_VBN DHA-2_NP ,_, was_VBD identified_VBN more_RBR recently_RB from_IN a_DT K._NP pneumoniae_NNS isolate_VBP in_IN France_NP ._SENT The_DT enzyme_NN also_RB confers_VBZ an_DT inducible_JJ beta-lactam_NN resistance_NN phenotype_NN ._SENT Recently_RB ,_, the_DT standard_JJ confirmatory_JJ test_NN for_IN the_DT detection_NN of_IN extended-spectrum_NN beta-lactamases_NNS revealed_VBD an_DT unusual_JJ ceftazidime_NN and_CC cefotaxime_NN resistance_NN phenotype_NN in_IN clinical_JJ isolates_NNS of_IN K._NP pneumoniae_NNS in_IN a_DT university_NN hospital_NN in_IN Taiwan_NP ._SENT Thus_RB ,_, a_DT retrospective_JJ analysis_NN was_VBD carried_VBN out_RP to_TO characterize_VB these_DT isolates_NNS and_CC their_PP$ various_JJ clinical_JJ and_CC epidemiological_JJ features_NNS ._SENT We_PP found_VBD inducible_JJ expression_NN of_IN DHA-1_NP by_IN these_DT isolates_NNS ._SENT To_TO our_PP$ knowledge_NN ,_, this_DT is_VBZ the_DT first_JJ report_NN of_IN the_DT appearance_NN of_IN DHA-1_NP in_IN the_DT Far_NP East_NP and_CC is_VBZ also_RB the_DT first_JJ report_NN of_IN fairly_RB widespread_JJ of_IN DHA-1-producing_NP K._NP pneumoniae_NNS within_IN a_DT health_NN care_NN institution_NN ._SENT Bacterial_JJ isolates_NNS and_CC patients_NNS ._SENT |_SYM The_DT standard_JJ screening_NN and_CC confirmation_NN methods_NNS for_IN the_DT detection_NN of_IN extended-spectrum_NN beta-lactamases_NNS were_VBD routinely_RB performed_VBN at_IN the_DT Department_NP of_IN Pathology_NP ,_, National_NP Cheng_NP Kung_NP University_NP Hospital_NP ,_, a_DT 900-bed_NN teaching_NN hospital_NN in_IN southern_JJ Taiwan_NP ._SENT Between_IN January_NP 1999_CD and_CC September_NP 2001_CD ,_, 10_CD nonrepetitive_JJ isolates_NNS of_IN K._NP pneumoniae_NNS from_IN 10_CD patients_NNS demonstrated_VBD reduced_VBN inhibition_NN zone_NN diameters_NNS for_IN both_DT ceftazidime_NN and_CC cefotaxime_NN in_IN combination_NN with_IN clavulanic_JJ acid_NN versus_IN those_DT for_IN ceftazidime_NN and_CC cefotaxime_NN when_WRB tested_VBN alone_RB (_( see_VB Table_NP )_) ,_, suggesting_VBG production_NN of_IN beta-lactamases_NNS induced_VBN by_IN clavulanic_JJ acid_NN ._SENT All_PDT these_DT isolates_NNS were_VBD identified_VBN by_IN conventional_JJ techniques_NNS and/or_CC the_DT API_NP 20E_JJ system_NN (_( bioMerieux_NP ,_, Marcy_NP l'Etoile_NP ,_, France_NP )_) ._SENT The_DT medical_JJ records_NNS of_IN the_DT patients_NNS from_IN whom_WP the_DT isolates_NNS were_VBD recovered_VBN were_VBD reviewed_VBN ._SENT Antagonism_NN testing_NN ._SENT |_SYM The_DT disk_NN antagonism_NN method_NN initially_RB used_VBN to_TO detect_VB inducibility_NN of_IN chromosomal_JJ beta-lactamases_NNS was_VBD performed_VBN with_IN a_DT slight_JJ modification_NN to_TO test_VB the_DT 10_CD K._NP pneumoniae_NNS isolates_NNS ._SENT Disks_NNS of_IN inducing_VBG agents_NNS and_CC disks_NNS of_IN cephalosporins_NNS were_VBD placed_VBN on_IN the_DT surface_NN of_IN Mueller-Hinton_NP agar_NN plates_NNS and_CC separated_VBN by_IN 25_CD mm_NN (_( see_VB Fig._NN )_) ._SENT The_DT cephalosporins_NNS used_VBN were_VBD cefotaxime_JJ ,_, ceftazidime_NN ,_, aztreonam_NP ,_, and_CC cefepime_NN ._SENT Clavulanic_JJ acid_NN (_( 10_CD mug_NN )_) and_CC cefoxitin_NN (_( 30_CD mug_NN )_) were_VBD used_VBN as_IN inducing_VBG agents_NNS ._SENT The_DT plates_NNS were_VBD examined_VBN after_IN overnight_JJ incubation_NN at_IN 37C_JJ ._SENT Susceptibility_NN testing_NN ._SENT |_SYM MICs_NP were_VBD determined_VBN by_IN the_DT standard_JJ agar_NN dilution_NN method_NN ._SENT The_DT antimicrobial_JJ agents_NNS and_CC their_PP$ sources_NNS were_VBD as_RB follows_VBZ :_: amoxicillin_NN and_CC clavulanic_JJ acid_NN ,_, SmithKline_NP Beecham_NP Pharmaceuticals_NPS ,_, Surrey_NP ,_, United_NP Kingdom_NP ;_: aztreonam_NP and_CC cefepime_NP ,_, Bristol-Myers_NP Squibb_NP ,_, New_NP Brunswick_NP ,_, N.J._NP ;_: cefotaxime_NN ,_, Hoechst-Roussel_NP Pharmaceuticals_NPS ,_, Inc._NP ,_, Somerville_NP ,_, N.J._NP ;_: cefoxitin_NN ,_, Sigma_NP Chemical_NP Company_NP ,_, St._NP Louis_NP ,_, Mo._NP ;_: ceftazidime_NN ,_, Glaxo_NP Group_NP Research_NP Ltd._NP ,_, Greenford_NP ,_, United_NP Kingdom_NP ;_: and_CC imipenem_NN ,_, Merck_NP Sharp_NP &_CC Dohme_NP ,_, West_NP Point_NP ,_, Pa._NP The_DT susceptibilities_NNS to_TO six_CD non-beta-lactam_NN agents_NNS were_VBD determined_VBN by_IN the_DT standard_JJ disk_NN diffusion_NN method_NN ._SENT Antimicrobial_JJ disks_NNS were_VBD obtained_VBN from_IN Becton_NP Dickinson_NP Microbiology_NP Systems_NP ,_, Cockeysville_NP ,_, Md._NP ,_, including_VBG amikacin_NN ,_, ciprofloxacin_NP ,_, gentamicin_NN ,_, ofloxacin_NP ,_, tobramycin_NN ,_, and_CC trimethoprim-sulfamethoxazole_NN ._SENT IEF_NP ._SENT |_SYM Crude_JJ preparations_NNS of_IN beta-lactamases_NNS were_VBD obtained_VBN from_IN the_DT isolates_NNS by_IN sonication_NN and_CC subjected_VBN to_TO analytical_JJ isoelectric_JJ focusing_VBG (_( IEF_NP )_) as_RB described_VBD previously_RB ._SENT Cells_NNS induced_VBN by_IN 16_CD mug_NN of_IN cefoxitin_NN per_IN ml_NN were_VBD incubated_VBN for_IN 3_CD h_NN before_IN harvesting_NN ._SENT beta-Lactamase_NN activity_NN was_VBD detected_VBN by_IN overlaying_VBG the_DT gels_NNS with_IN 0.5_CD mM_NP nitrocefin_NN in_IN 0.1_CD M_NP phosphate_NN buffer_NN ,_, pH_NN 7.0_CD ._SENT PCR_NP and_CC DNA_NP sequencing_NP ._SENT |_SYM Plasmids_NP from_IN the_DT isolates_NNS were_VBD extracted_VBN by_IN a_DT rapid_JJ alkaline_JJ lysis_NN procedure_NN and_CC used_VBN as_IN templates_NNS in_IN PCRs_NN ._SENT The_DT entire_JJ blaDHA-1_JJ gene_NN was_VBD amplified_VBN with_IN the_DT oligonucleotide_NN primers_NNS DHA-1A_NP (_( 5'-CTGATGAAAAAATCGTTATC-3_NP '_POS )_) and_CC DHA-1B_NP (_( 5'-ATTCCAGTGCACTCAAAATA-3_NP '_POS )_) ,_, corresponding_VBG to_TO nucleotides_NNS -3_CD to_TO 17_CD and_CC 1138_CD to_TO 1119_CD ,_, respectively_RB ,_, of_IN the_DT DHA-1_JJ structural_JJ gene_NN ._SENT The_DT PCR_NP conditions_NNS were_VBD as_RB follows_VBZ :_: 3_CD min_NN at_IN 94C_NN ;_: 35_CD cycles_NNS of_IN 1_CD min_NN at_IN 94C_NN ,_, 1_CD min_NN at_IN 55C_NN ,_, and_CC 1_CD min_NN at_IN 72C_NP ;_: and_CC finally_RB 7_CD min_NN at_IN 72C_NP ._SENT The_DT entire_JJ sequences_NNS of_IN blaTEM-_NN and_CC blaSHV-related_JJ genes_NNS were_VBD amplified_VBN with_IN the_DT primer_JJR pairs_NNS as_RB described_VBD previously_RB ._SENT The_DT amplicons_NNS were_VBD purified_VBN with_IN a_DT commercial_JJ kit_NN (_( Roche_NP Molecular_NP Biochemicals_NP ,_, Mannheim_NP ,_, Germany_NP )_) and_CC sequenced_JJ on_IN an_DT ABI_NP Prism_NN 310_CD sequencer_NN analyzer_NN (_( Applied_NP Biosystems_NP ,_, Foster_NP City_NP ,_, Calif._NP )_) ._SENT Transfer_NN of_IN resistance_NN ._SENT |_SYM Conjugation_NN experiments_NNS were_VBD performed_VBN as_IN described_VBN previously_RB with_IN streptomycin-resistant_JJ Escherichia_NP coli_NNS C600_NP as_IN the_DT recipient_NN ._SENT Tryptic_JJ soy_NN agar_NN plates_NNS supplemented_VBN with_IN 500_CD mug_NN of_IN streptomycin_NN (_( Sigma_NP )_) per_IN ml_NN and_CC 64_CD mug_NN of_IN cefoxitin_NN per_IN ml_NN were_VBD used_VBN to_TO select_VB the_DT transconjugants_NNS ._SENT K._NP pneumoniae_NNS strain_VBP W142_NP harboring_VBG blaCMY-8_NN was_VBD used_VBN as_IN the_DT control_NN ._SENT Plasmid_NP analysis_NN and_CC Southern_JJ hybridization_NN ._SENT |_SYM Plasmids_NP from_IN the_DT isolates_NNS were_VBD analyzed_VBN by_IN electrophoresis_NN on_IN a_DT 0.8_CD %_NN agarose_NN gel_NN ._SENT E._NP coli_NNS strain_VBP NCTC_NP 50192_CD (_( National_NP Collection_NP of_IN Type_NP Cultures_NP ,_, London_NP ,_, United_NP Kingdom_NP )_) ,_, which_WDT contained_VBD four_CD plasmids_NNS of_IN 7_CD ,_, 36.3_CD ,_, 63.8_CD ,_, and_CC 148.5_CD kb_NN ,_, was_VBD used_VBN as_IN a_DT source_NN of_IN molecular_JJ size_NN markers_NNS ._SENT The_DT gel_NN was_VBD stained_VBN with_IN ethidium_NN bromide_NN (_( Sigma_NP )_) ,_, visualized_VBN under_IN UV_NP light_NN ,_, and_CC subjected_VBN to_TO Southern_JJ hybridization_NN according_VBG to_TO the_DT original_JJ protocol_NN ._SENT The_DT blaDHA-1-specific_JJ probe_NN was_VBD a_DT PCR-generated_JJ amplicon_NN labeled_VBN with_IN [_SYM alpha-32P]dCTP_NN (_( Amersham_NP Pharmacia_NP Biotech_NP )_) by_IN the_DT random_JJ priming_NN technique_NN with_IN a_DT commercial_JJ kit_NN (_( Gibco-BRL_NP Life_NP Technologies_NPS ,_, Gaithersburg_NP ,_, Md._NP )_) ._SENT Ribotyping_NP ._SENT |_SYM The_DT chromosomal_JJ DNA_NN of_IN the_DT isolates_NNS was_VBD extracted_VBN and_CC purified_VBN as_IN described_VBN previously_RB ._SENT The_DT genomic_JJ DNA_NN was_VBD restricted_VBN with_IN EcoRI_NP or_CC BstEII_NP (_( Roche_NP Molecular_NP Biochemicals_NP )_) ._SENT The_DT digests_NNS of_IN chromosomal_JJ DNA_NN were_VBD electrophoresed_VBN at_IN 35_CD V_CD for_IN 18_CD h_NN in_IN a_DT 0.8_CD %_NN agarose_NN gel_NN ,_, transferred_VBN to_TO a_DT nylon_NN membrane_NN (_( Amersham_NP Pharmacia_NP Biotech_NP )_) ,_, and_CC then_RB hybridized_VBN with_IN a_DT [_SYM alpha-32P]dCTP-labeled_JJ cDNA_NN copy_NN of_IN E._NP coli_NNS rRNA_NN (_( Roche_NP Molecular_NP Biochemicals_NP )_) obtained_VBD by_IN reverse_JJ transcription_NN with_IN avian_JJ myeloblastosis_NN virus_NN reverse_NN transcriptase_NN (_( Gibco-BRL_NP )_) as_RB described_VBD previously_RB ._SENT FIG._NN 1_CD ._SENT |_SYM Double-disk_NP antagonism_NN tests_NNS with_IN 30_CD mug_NN of_IN cefoxitin_NN (_( A_NP )_) and_CC 10_CD mug_NN of_IN clavulanic_JJ acid_NN (_( B_NP )_) ._SENT Double-disk_NP antagonism_NN tests_NNS with_IN 30_CD mug_NN of_IN cefoxitin_NN (_( A_NP )_) and_CC 10_CD mug_NN of_IN clavulanic_JJ acid_NN (_( B_NP )_) ._SENT ATM_NN ,_, aztreonam_NP ;_: CAZ_NP ,_, ceftazidime_NN ;_: CLA_NP ,_, clavulanic_JJ acid_NN ;_: CTX_NP ,_, cefotaxime_NN ;_: FEP_NP ,_, cefepime_NN ;_: FOX_NP ,_, cefoxitin_NN ._SENT TABLE_NN 1_CD |_SYM Susceptibility_NN patterns_NNS of_IN DHA-1-producing_NP K._NP pneumoniae_NNS isolates_VBZ Inducibility_NN of_IN beta-lactamases_NNS ._SENT |_SYM In_IN the_DT standard_JJ extended-spectrum_NN beta-lactamases_NNS confirmatory_JJ test_NN ,_, the_DT reduced_VBN zone_NN diameters_NNS for_IN ceftazidime_NN and_CC cefotaxime_NN in_IN combination_NN with_IN clavulanic_JJ acid_NN versus_IN those_DT for_IN ceftazidime_NN and_CC cefotaxime_NN tested_VBN alone_RB among_IN the_DT 10_CD K._NP pneumoniae_NNS isolates_NNS ranged_VBD from_IN 2_CD to_TO 10_CD mm_NN (_( mean_VB ,_, 5.6_CD mm_NN )_) and_CC 3_CD to_TO 8_CD mm_NN (_( mean_VB ,_, 5.6_CD mm_NN )_) ,_, respectively_RB ,_, suggesting_VBG production_NN of_IN beta-lactamases_NNS induced_VBN by_IN clavulanic_JJ acid_NN ._SENT Inducibility_NN of_IN the_DT beta-lactamases_NNS was_VBD further_RBR recognized_VBN by_IN the_DT disk_NN antagonism_NN test_NN ,_, which_WDT demonstrated_VBD blunting_VBG of_IN the_DT cephalosporin_NN disks_NNS adjacent_JJ to_TO the_DT cefoxitin_NN and_CC clavulanic_JJ acid_JJ disks_NNS ._SENT Susceptibility_NN testing_NN ._SENT |_SYM The_DT results_NNS of_IN the_DT susceptibility_NN tests_NNS are_VBP shown_VBN in_IN Table_NP ._SENT All_DT 10_CD isolates_NNS exhibited_VBN high-level_JJ resistance_NN to_TO amoxicillin-clavulanic_JJ acid_NN and_CC cefoxitin_NN ._SENT In_IN the_DT presence_NN of_IN clavulanic_JJ acid_NN ,_, a_DT one_CD to_TO four_CD twofold_JJ concentration_NN increase_NN in_IN the_DT MICs_NN of_IN ceftazidime_NN ,_, cefotaxime_NN ,_, and_CC aztreonam_NP was_VBD noted_VBN ,_, while_IN the_DT changes_NNS after_IN addition_NN of_IN clavulanic_JJ acid_NN in_IN the_DT MICs_NN of_IN cefepime_NN and_CC imipenem_NN were_VBD not_RB obvious_JJ ._SENT Identification_NN of_IN beta-lactamases_NNS ._SENT |_SYM IEF_NP demonstrated_VBD that_IN all_DT 10_CD isolates_NNS displayed_VBD three_CD bands_NNS of_IN beta-lactamase_NN activity_NN with_IN pIs_NNS of_IN 5.4_CD ,_, 7.6_CD ,_, and_CC 7.8_CD ._SENT The_DT pI_NP 7.6_CD band_NN probably_RB represented_VBD the_DT chromosomal_JJ SHV-1_NP or_CC SHV-11_NP type_NN beta-lactamase_NN of_IN K._NP pneumoniae_NNS ,_, the_DT pI_NP 5.4_CD band_NN might_MD represent_VB the_DT TEM-1_JJ beta-lactamase_NN ,_, and_CC the_DT pI_NP 7.8_CD band_NN might_MD represent_VB the_DT beta-lactamase_NN responsible_JJ for_IN the_DT inducible_JJ resistance_NN phenotype_NN ._SENT A_DT 1,141-bp_JJ fragment_NN was_VBD amplified_VBN by_IN PCR_NP with_IN the_DT blaDHA-1-specific_JJ primers_NNS for_IN all_DT 10_CD K._NP pneumoniae_NNS isolates_NNS ._SENT The_DT amino_NN acid_NN sequences_NNS of_IN the_DT PCR_NP products_NNS deduced_VBN from_IN the_DT sequence_NN analysis_NN were_VBD identical_JJ to_TO the_DT plasmid-mediated_JJ cephalosporinase_NN DHA-1_NP from_IN S._NP enterica_NP serovar_NP Enteritidis_NP ._SENT The_DT DHA-1_NP cephalosporinase_NN was_VBD consistent_JJ with_IN the_DT pI_NP 7.8_CD beta-lactamase_NN demonstrated_VBN by_IN IEF_NP ._SENT All_PDT the_DT isolates_NNS also_RB carried_VBD blaTEM-1_JJ and_CC blaSHV-11_JJ ,_, which_WDT were_VBD identified_VBN by_IN PCR_NP with_IN the_DT blaTEM-_NN and_CC blaSHV-specific_JJ primers_NNS and_CC sequence_NN analysis_NN ._SENT Conjugation_NN experiments_NNS and_CC plasmid_NN analysis_NN ._SENT |_SYM Conjugation_NP experiments_NNS failed_VBD to_TO demonstrate_VB transfer_NN of_IN inducible_JJ cephalosporin_NN resistance_NN from_IN any_DT of_IN the_DT isolates_NNS ._SENT Cefoxitin_NP resistance_NN was_VBD transferred_VBN from_IN the_DT control_NN strain_NN to_TO E._NP coli_NNS C600_NP at_IN a_DT frequency_NN of_IN 10-3_CD to_TO 10-4_CD per_IN donor_NN cell_NN ._SENT Six_CD different_JJ profiles_NNS were_VBD demonstrated_VBN by_IN plasmid_NN analysis_NN among_IN the_DT 10_CD isolates_NNS ._SENT In_IN all_DT isolates_NNS analyzed_VBD ,_, the_DT presence_NN of_IN a_DT plasmid_NN of_IN approximately_RB 70_CD kb_NN was_VBD detected_VBN ._SENT Southern_JJ hybridization_NN with_IN the_DT blaDHA-1-specific_JJ probe_NN showed_VBD that_IN blaDHA-1_NN was_VBD located_VBN on_IN the_DT 70-kb_JJ plasmid_NN (_( data_NNS not_RB shown_VBN )_) ._SENT Ribotyping_NP ._SENT |_SYM The_DT genetic_JJ relationship_NN among_IN the_DT 10_CD K._NP pneumoniae_NNS isolates_NNS was_VBD investigated_VBN by_IN ribotyping_NN with_IN two_CD different_JJ endonucleases_NNS ._SENT Patterns_NNS with_IN at_IN least_JJS two_CD discordant_JJ bands_NNS were_VBD considered_VBN different_JJ ._SENT The_DT results_NNS are_VBP listed_VBN in_IN Table_NP and_CC partially_RB shown_VBN in_IN Fig._NN ._SENT Both_DT EcoRI_NP and_CC BstEII_NP generated_VBD seven_CD different_JJ patterns_NNS ._SENT Isolates_NNS 1490_CD and_CC 1596_CD ,_, both_CC of_IN which_WDT were_VBD collected_VBN in_IN early_JJ 2000_CD ,_, and_CC isolates_VBZ 197_CD ,_, 274_CD ,_, and_CC 281_CD ,_, which_WDT were_VBD all_RB collected_VBN in_IN late_JJ 2000_CD ,_, had_VBD identical_JJ ribotypes_NNS ,_, suggesting_VBG that_IN they_PP derived_VBD from_IN two_CD endemic_JJ clones_NNS ._SENT Clinical_JJ characteristics_NNS ._SENT |_SYM Three_CD isolates_NNS were_VBD recovered_VBN from_IN sputum_NN samples_NNS and_CC were_VBD considered_VBN colonizers_NNS ._SENT The_DT other_JJ seven_CD isolates_NNS were_VBD associated_VBN with_IN three_CD urinary_JJ tract_NN infections_NNS ,_, two_CD wound_NN infections_NNS ,_, one_CD intra-abdominal_JJ infection_NN ,_, and_CC one_CD bloodstream_NN infection_NN ._SENT The_DT clinical_JJ characteristics_NNS of_IN the_DT patients_NNS infected_VBN with_IN or_CC colonized_VBN by_IN the_DT DHA-1-producing_NN isolates_NNS are_VBP summarized_VBN in_IN Table_NP ._SENT Six_CD patients_NNS had_VBD undergone_VBN hemodialysis_NN due_JJ to_TO either_DT chronic_JJ or_CC acute_JJ renal_JJ failure_NN before_IN isolation_NN ._SENT Five_CD isolates_NNS were_VBD obtained_VBN >48_JJ h_NN after_IN the_DT patients_NNS were_VBD admitted_VBN to_TO the_DT hospital_NN ._SENT Three_CD of_IN the_DT five_CD isolates_NNS were_VBD from_IN the_DT patients_NNS in_IN the_DT surgery_NN wards_NNS ,_, and_CC two_CD isolates_NNS were_VBD from_IN the_DT patients_NNS in_IN the_DT intensive_JJ care_NN units_NNS ._SENT Although_IN the_DT remaining_VBG five_CD isolates_NNS were_VBD obtained_VBN within_IN 48_CD h_NN after_IN the_DT current_JJ admission_NN ,_, all_DT patients_NNS with_IN these_DT isolates_NNS had_VBD been_VBN hospitalized_VBN in_IN the_DT teaching_NN hospital_NN 1_CD to_TO 5_CD months_NNS earlier_RBR ._SENT Notably_RB ,_, four_CD of_IN them_PP had_VBD been_VBN on_IN hemodialysis_NN either_CC in_IN the_DT university_NN hospital_NN or_CC at_IN community_NN hospitals_NNS ._SENT All_DT nine_CD patients_NNS for_IN whom_WP complete_JJ medical_JJ records_NNS were_VBD available_JJ had_VBD been_VBN exposed_VBN to_TO beta-lactam_NN agents_NNS within_IN 2_CD weeks_NNS before_IN isolation_NN of_IN the_DT DHA-1_JJ producers_NNS ._SENT Patients_NNS 3_CD ,_, 4_CD ,_, 6_CD ,_, and_CC 8_CD received_VBD no_DT specific_JJ antimicrobial_JJ agents_NNS for_IN the_DT DHA-1_JJ producers_NNS ,_, and_CC patient_JJ 7_CD was_VBD not_RB treated_VBN for_IN the_DT urinary_JJ tract_NN infection_NN at_IN the_DT university_NN hospital_NN ._SENT Patients_NNS 2_CD and_CC 9_CD received_VBN ciprofloxacin_NN and_CC trimethoprim-sulfamethoxazole_NN ,_, respectively_RB ,_, for_IN 2_CD weeks_NNS ,_, and_CC the_DT K._NP pneumoniae_NN strains_NNS were_VBD not_RB isolated_VBN from_IN urine_NN samples_NNS afterward_RB ._SENT Patient_NP 1_CD had_VBD received_VBN cefotaxime_NN and_CC ciprofloxacin_NN ,_, but_CC his_PP$ deep_JJ soft_JJ tissue_NN infection_NN was_VBD not_RB eradicated_VBN until_IN debridement_NN was_VBD performed_VBN 1_CD month_NN after_IN admission_NN ._SENT Patient_NN 5_CD received_VBN cefotaxime_NN after_IN isolation_NN and_CC died_VBD of_IN intra-abdominal_JJ hemorrhages_NNS and_CC multiorgan_NN failure_NN due_JJ to_TO his_PP$ underlying_VBG diseases_NNS 1_CD week_NN later_RBR ._SENT Whether_IN the_DT bacterial_JJ peritonitis_NN was_VBD persistent_JJ before_IN his_PP$ death_NN is_VBZ not_RB clear_JJ ._SENT Patient_NN 10_CD was_VBD cured_VBN of_IN the_DT bloodstream_NN infection_NN with_IN 2_CD weeks_NNS of_IN meropenem_NN and_CC netilmicin_NN therapy_NN ._SENT Five_CD patients_NNS died_VBN during_IN hospitalization_NN ,_, and_CC patient_JJ 7_CD died_VBD during_IN the_DT other_JJ hospitalization_NN ;_: however_RB ,_, none_NN of_IN the_DT deaths_NNS were_VBD directly_RB due_JJ to_TO infections_NNS caused_VBN by_IN the_DT DHA-1_JJ producers_NNS ._SENT FIG._NN 2_CD ._SENT |_SYM Plasmid_NP profiles_NNS of_IN the_DT 10_CD K._NP pneumoniae_NNS Plasmid_NP profiles_NNS of_IN the_DT 10_CD K._NP pneumoniae_NNS isolates_NNS ._SENT Lanes_NNS 1_CD to_TO 10_CD ,_, isolates_VBZ 387_CD ,_, 416_CD ,_, 1490_CD ,_, 1596_CD ,_, 197_CD ,_, 274_CD ,_, 281_CD ,_, 325_CD ,_, 397_CD ,_, and_CC 1067_CD ,_, respectively_RB ;_: lane_JJ M_NP ,_, E._NP coli_NNS NCTC_NP 50192_CD ,_, which_WDT contains_VBZ four_CD plasmids_NNS with_IN molecular_JJ sizes_NNS of_IN 7_CD ,_, 36.2_CD ,_, 63.8_CD ,_, and_CC 148.5_CD kb_NN ._SENT FIG._NN 3_CD ._SENT |_SYM Ribotypes_NP generated_VBN by_IN EcoRI_NP ._SENT Ribotypes_NNS generated_VBN by_IN EcoRI_NP ._SENT Lane_NP 1_CD ,_, molecular_JJ size_NN marker_NN kit_NN II_NP (_( Roche_NP Molecular_NP Biochemicals_NP )_) ;_: lanes_NNS 2_CD to_TO 11_CD ,_, isolates_VBZ 387_CD ,_, 416_CD ,_, 1490_CD ,_, 1596_CD ,_, 197_CD ,_, 274_CD ,_, 281_CD ,_, 325_CD ,_, 397_CD ,_, and_CC 1067_CD ,_, respectively_RB ;_: lane_NN 12_CD ,_, 1-kb_JJ ladder_NN (_( Promega_NP Co._NP ,_, Madison_NP ,_, Wis._NP )_) ._SENT TABLE_NN 2_CD |_SYM Clinical_JJ data_NNS ,_, plasmid_NN profiles_NNS ,_, and_CC ribotypes_NNS of_IN the_DT 10_CD DHA-1-producing_NP K._NP pneumoniae_NP isolates_VBZ The_DT plasmid-mediated_JJ inducible_JJ DHA-1_NP beta-lactamase_NN was_VBD first_RB identified_VBN in_IN Taiwan_NP in_IN the_DT present_JJ study_NN ._SENT PCR_NP ,_, sequence_NN analysis_NN ,_, and_CC IEF_NP revealed_VBD production_NN of_IN three_CD beta-lactamases_NNS ,_, TEM-1_NP ,_, SHV-11_NP ,_, and_CC DHA-1_NP ,_, by_IN all_DT 10_CD K._NP pneumoniae_NNS isolates_VBZ possessing_VBG inducible_JJ resistance_NN to_TO extended-spectrum_NN beta-lactamases_NNS ._SENT TEM-1_NP and_CC SHV-11_NP are_VBP restricted-spectrum_NN beta-lactamases_NNS ._SENT Since_IN DHA-1_NP ,_, originally_RB found_VBN in_IN an_DT S._NP enterica_NP serovar_NP Enteritidis_NP strain_NN was_VBD inducible_JJ ,_, the_DT enzyme_NN is_VBZ believed_VBN to_TO be_VB responsible_JJ for_IN the_DT unusual_JJ inducible_JJ beta-lactam_NN resistance_NN phenotype_NN of_IN our_PP$ isolates_NNS ._SENT Transfer_NN of_IN the_DT resistance_NN by_IN conjugation_NN experiments_NNS was_VBD not_RB successful_JJ ;_: however_RB ,_, the_DT blaDHA-1-specific_JJ probe_NN was_VBD hybridized_VBN to_TO a_DT 70-kb_JJ plasmid_NN in_IN all_DT isolates_NNS analyzed_VBD ,_, suggesting_VBG that_IN blaDHA-1_NN was_VBD on_IN non-self-transmissible_JJ plasmids_NNS ._SENT Similar_JJ results_NNS have_VBP been_VBN described_VBN in_IN reports_NNS of_IN DHA-1-producing_NP S._NP enterica_NP serovar_NP Enteritidis_NP and_CC DHA-2-producing_NP K._NP pneumoniae_NNS ._SENT To_TO our_PP$ knowledge_NN ,_, plasmid-mediated_JJ DHA-type_NP beta-lactamases_NNS have_VBP only_RB been_VBN reported_VBN in_IN isolates_NNS from_IN Europe_NP and_CC the_DT Middle_NP East_NP ._SENT Thus_RB ,_, this_DT is_VBZ also_RB the_DT first_JJ report_NN of_IN the_DT appearance_NN of_IN a_DT DHA-type_NP beta-lactamase_NN in_IN the_DT Far_NP East_NP ._SENT In_IN the_DT extended-spectrum_NN beta-lactamases_VBZ confirmatory_JJ test_NN ,_, all_DT K._NP pneumoniae_NNS isolates_NNS revealed_VBD decreased_VBN inhibition_NN zone_NN diameters_NNS for_IN ceftazidime_NN and_CC cefotaxime_NN in_IN combination_NN with_IN clavulanic_JJ acid_NN compared_VBN with_IN those_DT of_IN these_DT two_CD agents_NNS tested_VBN alone_RB ,_, indicating_VBG that_IN the_DT test_NN could_MD also_RB be_VB used_VBN to_TO screen_VB for_IN inducible_JJ beta-lactamase-producing_JJ gram-negative_JJ bacilli_NNS that_WDT naturally_RB lack_VBP inducible_JJ chromosome-mediated_JJ AmpC_NP enzymes_NNS ._SENT All_DT 10_CD K._NP pneumoniae_NNS isolates_NNS showed_VBD blunting_VBG of_IN the_DT cephalosporin_NN disks_NNS adjacent_JJ to_TO the_DT cefoxitin_NN and_CC clavulanic_JJ acid_JJ disks_NNS in_IN the_DT antagonism_NN test_NN ,_, indicating_VBG that_IN the_DT test_NN can_MD also_RB be_VB used_VBN to_TO recognize_VB plasmid-mediated_JJ beta-lactamases_NNS ._SENT In_IN the_DT Enterobacteriaceae_NP ,_, AmpC-hyperproducing_JJ derepressed_JJ strains_NNS appear_VBP frequently_RB in_IN infections_NNS caused_VBN by_IN organisms_NNS naturally_RB producing_VBG inducible_JJ AmpC_NP enzymes_NNS when_WRB patients_NNS are_VBP treated_VBN with_IN extended-spectrum_NN beta-lactams_NNS ._SENT Therefore_RB ,_, it_PP has_VBZ been_VBN recommended_VBN that_IN the_DT inducible-AmpC-producing_JJ Enterobacteriaceae_NP species_NNS should_MD be_VB reported_VBN as_IN resistant_NN to_TO all_DT extended-spectrum_NN beta-lactams_NNS ._SENT The_DT use_NN of_IN extended-spectrum_NN beta-lactams_NNS should_MD be_VB restricted_VBN accordingly_RB ._SENT Studies_NNS on_IN determining_VBG the_DT therapeutic_JJ success_NN or_CC failure_NN of_IN extended-spectrum_NN third-generation_NN cephalosporins_NNS in_IN treating_VBG infections_NNS with_IN plasmid-mediated_JJ inducible_JJ AmpC_NP producers_NNS ,_, such_JJ as_IN our_PP$ DHA-1-producing_NP K._NP pneumoniae_NP isolates_VBZ ,_, are_VBP lacking_VBG ._SENT Therefore_RB ,_, whether_IN such_JJ K._NP pneumoniae_NNS strains_NNS ,_, like_IN gram-negative_JJ organisms_NNS naturally_RB producing_VBG inducible_JJ AmpC_NP enzymes_NNS ,_, should_MD also_RB be_VB reported_VBN as_IN resistant_NN to_TO all_DT third-generation_NN cephalosporins_NNS is_VBZ not_RB known_VBN and_CC deserves_VBZ further_JJR investigation_NN ._SENT The_DT drugs_NNS of_IN choice_NN for_IN the_DT treatment_NN of_IN infections_NNS with_IN such_JJ organisms_NNS are_VBP also_RB undetermined_JJ ._SENT Based_VBN on_IN MIC_JJ data_NNS and_CC the_DT confirmatory_JJ test_NN for_IN extended-spectrum_NN beta-lactamases_NNS ,_, a_DT majority_NN of_IN the_DT DHA-1-producing_NP K._NP pneumoniae_NNS isolates_NNS would_MD not_RB have_VB been_VBN reported_VBN as_RB resistant_JJ to_TO all_DT third-generation_NN cephalosporins_NNS ._SENT However_RB ,_, after_IN induction_NN by_IN clavulanic_JJ acid_NN ,_, these_DT isolates_NNS showed_VBD reduced_VBN susceptibilities_NNS to_TO these_DT agents_NNS ._SENT Moreover_RB ,_, all_PDT these_DT isolates_NNS remained_VBD susceptible_JJ to_TO cefepime_NN and_CC imipenem_NN even_RB in_IN the_DT presence_NN of_IN clavulanic_JJ acid_NN ._SENT Thus_RB ,_, fourth-generation_NN cephalosporins_NNS and_CC carbapenems_NNS could_MD be_VB better_JJR choices_NNS for_IN the_DT treatment_NN of_IN infections_NNS caused_VBN by_IN DHA-1_JJ producers_NNS ._SENT Alternatively_RB ,_, when_WRB the_DT presence_NN of_IN inducible_JJ DHA-type_NP enzymes_NNS is_VBZ suspected_VBN or_CC detected_VBN ,_, physicians_NNS should_MD be_VB informed_VBN ,_, and_CC the_DT use_NN of_IN strong_JJ AmpC-inducing_JJ agents_NNS ,_, such_JJ as_IN clavulanic_JJ acid_NN and_CC cephamycins_NNS ,_, should_MD be_VB avoided_VBN ._SENT Six_CD plasmid_NP patterns_NNS and_CC seven_CD ribotypes_NNS were_VBD found_VBN among_IN the_DT 10_CD DHA-1-producing_NN isolates_VBZ (_( Fig._NN and_CC )_) ,_, indicating_VBG that_IN the_DT spread_NN of_IN blaDHA-1_NN was_VBD due_JJ to_TO both_DT dissemination_NN of_IN endemic_JJ clones_NNS and_CC horizontal_JJ transfer_NN of_IN the_DT resistance_NN gene_NN ._SENT Most_JJS isolates_NNS in_IN the_DT university_NN hospital_NN were_VBD obtained_VBN from_IN surgery_NN wards_NNS and_CC intensive_JJ care_NN units_NNS ._SENT Five_CD isolates_NNS were_VBD obtained_VBN within_IN 48_CD h_NN after_IN admission_NN ;_: however_RB ,_, all_DT patients_NNS from_IN whom_WP the_DT isolates_NNS were_VBD obtained_VBN had_VBD been_VBN hospitalized_VBN in_IN the_DT same_JJ university_NN hospital_NN 1_CD to_TO 5_CD months_NNS before_IN the_DT current_JJ admissions_NNS ._SENT It_PP is_VBZ not_RB known_VBN exactly_RB whether_IN these_DT isolates_NNS were_VBD from_IN the_DT university_NN medical_JJ center_NN or_CC other_JJ hospitals_NNS ._SENT However_RB ,_, since_RB isolates_VBZ 274_CD and_CC 281_CD had_VBD a_DT ribotype_NN identical_JJ to_TO that_DT of_IN isolate_NN 197_CD ,_, which_WDT was_VBD obviously_RB from_IN the_DT university_NN hospital_NN ,_, it_PP is_VBZ very_RB likely_JJ that_IN at_IN least_JJS patients_NNS 6_CD and_CC 7_CD had_VBD acquired_VBN the_DT resistance_NN strain_NN during_IN previous_JJ hospitalizations_NNS ._SENT Six_CD of_IN the_DT 10_CD patients_NNS infected_VBN with_IN DHA-1_NP producers_NNS had_VBD been_VBN on_IN hemodialysis_NN ._SENT Since_IN this_DT was_VBD a_DT retrospective_JJ study_NN ,_, it_PP is_VBZ not_RB clear_JJ whether_IN the_DT nosocomial_JJ infections_NNS were_VBD associated_VBN with_IN the_DT hemodialysis_NN systems_NNS ._SENT In_IN conclusion_NN ,_, sporadic_JJ infections_NNS with_IN K._NP pneumoniae_NNS possessing_VBG an_DT unusual_JJ inducible_JJ beta-lactam_NN resistance_NN phenotype_NN were_VBD found_VBN in_IN a_DT university_NN hospital_NN in_IN Taiwan_NP ._SENT DHA-1_NP encoded_VBD by_IN non-self-transferable_JJ plasmids_NNS conferred_VBD the_DT resistance_NN phenotype_NN ._SENT The_DT spread_NN of_IN the_DT DHA-1_NP producers_NNS was_VBD due_JJ to_TO dissemination_NN of_IN endemic_JJ clones_NNS and_CC horizontal_JJ transfer_NN of_IN the_DT resistance_NN gene_NN ._SENT 